Ai-Min Hui
Executive President of Fosun Pharma President of Global R & d, CMO and Chair of Scientific Committee @Fosun Pharma
Signup · Get unlimited contacts
WORK HISTORY
Executive President of Fosun Pharma President of Global R & d, CMO and Chair of Scientific Committee @Fosun Pharma
Since joined Fosun Pharma in Nov. 2017, with increasing responsibilities, he has been fully in charge of global discovery, development and registration of all R&D pipelines and products; also responsible for the scientific and medical evaluation of license-in, investment, and M&A business of Fosun Pharma and Fosun International Healthcare. During a period of over 4 years, he led the transformation of R&D of the company, and made multiple zero-breakthrough achievements in Fosun’s history: Increased clinical programs of innovative drug 40 times from 1 only to over 40 Established Fosun Pharma Global R&D Center and has served as the funding President Build up a US/EU R&D center starting 2018 Initiated 1st clinical trial (FCN-1501) outside of China (in US and Australia simultaneously) in 2018 Initiated 1st First-in-class drug (ORIN-1001) clinical trial in US in 2019 Granted 1st Fast Track Designation by FDA in 2019 (ORIN-1001) Granted 1st Orphan indication by FDA in 2019 (FCN-1501) Appointed as the Director of the Shanghai Key Laboratory of Stem Cell Therapy in 2019 Led the approval and launch of Fosun Pharma\'s first innovative drug Avatripapax in China in 2020 Witnessed and helped in the development and launch of the first CAR-T therapy in China, YESCARTA (2021), and the first biosimilar in China (Rituximab, 2019) Published the first scientific paper in Fosun Pharma’s history; also published multiple papers in Nature Med, Lancet, et al as First and/or corresponding authorsIn late January 2020, he initiated and led the deal finding, contract signing, and the joint development, registration and launch of mRNA COVID-19 vaccine BNT162b2 in Greater China (named as FUBITAI, a.k.a. Comirnaty® outside of China) between BioNTech and Fosun Pharma; initiated animal protection study, Ph 1 and Ph 2 clinical trials in China in 2020; FUBITAI has been approved in Hong Kong, Macao, and Taiwan in 2021.
EDUCATION
National Cancer Center at Tokyo
Post-Doctoral Fellow, Cancer Biology
Shinshu University Medical School (Japan)
PhD, Molecular Biology
Hebei Medical University
MD, Medicine
SKILLS
ABOUT AI-MIN HUI
mRNA COVID-19 vaccine: in late January 2020, Dr. Hui initiated and led the deal finding, contract agreement signing, and the joint research/development, registration and launch of mRNA COVID-19 vaccine BNT162b2 in Greater China (named as FUBITAI, a.k.a. Comirnaty® outside of China) between BioNTech and Fosun Pharma; initiated animal protection study (Apr. 2020), Ph 1 (July 2020) and Ph 2 (Nov. 2020) clinical trials in China; FUBITAI has been approved in Hong Kong (Feb.), Macao (March), and Taiwan (Sept.) in 2021.Dr. Hui has directly led the global development and registration of multiple small molecule and biologic anti-cancer drugs including Ixazomib, Isatuximab (anti-CD38) et al. In China, Dr. Hui also has led the development and launch of multiple innovative drugs including Ninlaro, Aatrombopag, FUBITAI, et al. He also witnessed and helped in the development and launch of the first CAR-T therapy Yescarta in China, and the first biosimilarRituximab in China. DR. Hui has personally led or participated in over 60 meetings with FDA, CDE (China), EMA, PMDA (Japan) and other Agencies globally.Dr. Hui has over 20 years of experiences in cancer biology, translational oncology and innovative drug development in world\'s top academic medical centers (National Cancer Institute [NCI], National Cancer Center at Tokyo, Uni. of Tokyo Hospital) and pharmaceutical companies Sanofi, Millennium/Takeda, GE Healthcare, Fosun Pharma. Dr. Hui has granted over 20 international and national scientific awards including the 4th China Translational Medicine Award - International Collaboration Award (2021), 2020 Jishi Award - Top 10 Drug Innovation Scientists, 2020 Jishi Drug Innovation Pioneer Award, Young Investigator Award at the First International Conference on Gastrointestinal Tumorigenesis (1996), Young Investigator Award of the Japanese Society of Gastroenterology and Surgery (1993), et al. Dr Hui has published 100 peer-reviewed articles on top scientific journals including The New England Journal of Medicine, Nature Medicine, The Lancet, Cancer Cell, et al, and authored or co-authored 10 Scientific books including the “Molecular Genetics of Cancer”.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.